MARKET

IFRX

IFRX

Inflarx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.680
+0.060
+1.30%
Opening 11:44 07/02 EDT
OPEN
4.630
PREV CLOSE
4.620
HIGH
4.710
LOW
4.560
VOLUME
75.43K
TURNOVER
--
52 WEEK HIGH
9.70
52 WEEK LOW
2.170
MARKET CAP
121.51M
P/E (TTM)
-2.1518
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IFRX stock price target is 9.34 with a high estimate of 20.01 and a low estimate of 3.001.

EPS

IFRX News

More
Hedge Funds Are Buying InflaRx N.V. (IFRX)
Insider Monkey · 6d ago
CLIR, IDEX, ENPH and BBI among midday movers
Seeking Alpha - Article · 06/17 16:41
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
GlobeNewswire · 06/17 12:30
NCLH, DKNG among premarket losers
Seeking Alpha - Article · 06/17 12:18
InflaRx reports underwhelming data from study of IFX-1 in COVID-19
Seeking Alpha - Article · 06/17 12:11
BTIG Initiates Coverage On InflaRx with Buy Rating, Announces Price Target of $12
BTIG analyst Dae Gon Ha initiates coverage on InflaRx (NASDAQ:IFRX) with a Buy rating and announces Price Target of $12.
Benzinga · 06/17 10:23
InflaRx (IFRX): Strong Industry, Solid Earnings Estimate Revisions
Zacks · 06/11 13:30
The Zacks Analyst Blog Highlights: Bayer Aktiengesellschaft, InflaRx, Legrand, Innate Pharma and DiaSorin
Zacks · 05/29 16:10

Industry

Biotechnology & Medical Research
+1.30%
Pharmaceuticals & Medical Research
+0.85%

Hot Stocks

Symbol
Price
%Change

About IFRX

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
More

Webull offers kinds of Inflarx NV stock information, including NASDAQ:IFRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IFRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IFRX stock methods without spending real money on the virtual paper trading platform.